PMID- 16635254
OWN - NLM
STAT- MEDLINE
DCOM- 20060523
LR  - 20131121
IS  - 0022-3042 (Print)
IS  - 0022-3042 (Linking)
VI  - 97 Suppl 1
DP  - 2006 Apr
TI  - Semax, an analogue of adrenocorticotropin (4-10), binds specifically and 
      increases levels of brain-derived neurotrophic factor protein in rat basal 
      forebrain.
PG  - 82-6
AB  - The heptapeptide Semax (Met-Glu-His-Phe-Pro-Gly-Pro) is an analogue of the 
      N-terminal fragment (4-10) of adrenocorticotropic hormone which, after intranasal 
      application, has profound effects on learning and memory formation in rodents and 
      humans, and also exerts marked neuroprotective effects. A clue to the molecular 
      mechanism underlying this neurotropic action was recently given by the 
      observation that Semax stimulates the synthesis of brain-derived neurotrophic 
      factor (BDNF), a potent modulator of synaptic plasticity, in astrocytes cultured 
      from rat basal forebrain. In the present study, we investigated whether Semax 
      affects BDNF levels in rat basal forebrain upon intranasal application of the 
      peptide. In addition, we examined whether cell membranes isolated from this brain 
      region contained binding sites for Semax. The binding of tritium-labelled Semax 
      was found to be time dependent, specific and reversible. Specific Semax binding 
      required calcium ions and was characterized by a mean+/-SEM dissociation constant 
      (KD) of 2.4+/-1.0 nm and a BMAX value of 33.5+/-7.9 fmol/mg protein. Sandwich 
      immunoenzymatic analysis revealed that Semax applied intranasally at 50 and 250 
      microg/kg bodyweight resulted in a rapid increase in BDNF levels after 3 h in the 
      basal forebrain, but not in the cerebellum. These results point to the presence 
      of specific binding sites for Semax in the rat basal forebrain. In addition, 
      these findings indicate that the cognitive effects exerted by Semax might be 
      associated, at least in part, with increased BDNF protein levels in this brain 
      region.
FAU - Dolotov, Oleg V
AU  - Dolotov OV
AD  - Institute of Molecular Genetics, Russian Academy of Sciences, Moscow, Russian 
      Federation.
FAU - Karpenko, Ekaterina A
AU  - Karpenko EA
FAU - Seredenina, Tamara S
AU  - Seredenina TS
FAU - Inozemtseva, Lyudmila S
AU  - Inozemtseva LS
FAU - Levitskaya, Natalia G
AU  - Levitskaya NG
FAU - Zolotarev, Yuriy A
AU  - Zolotarev YA
FAU - Kamensky, Andrey A
AU  - Kamensky AA
FAU - Grivennikov, Igor A
AU  - Grivennikov IA
FAU - Engele, Juergen
AU  - Engele J
FAU - Myasoedov, Nikolay F
AU  - Myasoedov NF
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - J Neurochem
JT  - Journal of neurochemistry
JID - 2985190R
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - 0 (Neuroprotective Agents)
RN  - 0 (Peptide Fragments)
RN  - 0 (RNA, Messenger)
RN  - 10028-17-8 (Tritium)
RN  - 42Z2K6ZL8P (Manganese)
RN  - 80714-61-0 (ACTH (4-7), Pro-Gly-Pro-)
RN  - 9002-60-2 (Adrenocorticotropic Hormone)
RN  - SY7Q814VUP (Calcium)
SB  - IM
MH  - Administration, Intranasal
MH  - Adrenocorticotropic Hormone/*analogs & derivatives/metabolism/pharmacology
MH  - Animals
MH  - Brain-Derived Neurotrophic Factor/genetics/*metabolism
MH  - Calcium/pharmacology
MH  - Cell Membrane/metabolism
MH  - Cells, Cultured
MH  - Immunoenzyme Techniques
MH  - Male
MH  - Manganese/pharmacology
MH  - *Neuroprotective Agents/metabolism/pharmacology
MH  - Peptide Fragments/*metabolism/*pharmacology
MH  - Prosencephalon/*drug effects/*metabolism
MH  - RNA, Messenger/analysis
MH  - Rats
MH  - Rats, Wistar
MH  - Tritium
EDAT- 2006/04/26 09:00
MHDA- 2006/05/24 09:00
CRDT- 2006/04/26 09:00
PHST- 2006/04/26 09:00 [pubmed]
PHST- 2006/05/24 09:00 [medline]
PHST- 2006/04/26 09:00 [entrez]
AID - JNC3658 [pii]
AID - 10.1111/j.1471-4159.2006.03658.x [doi]
PST - ppublish
SO  - J Neurochem. 2006 Apr;97 Suppl 1:82-6. doi: 10.1111/j.1471-4159.2006.03658.x.